
Quarterly report 2025-Q3
added 11-06-2025
Organovo Holdings Net Debt 2011-2026 | ONVO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.4 M | -1.51 M | -13.5 M | - | -27.4 M | -36.5 M | -43.7 M | -62.8 M | -62.1 M | -50.1 M | -48.2 M | -15.6 M | -14.8 M | -1.78 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.78 K | -62.8 M | -29.7 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Brainsway Ltd.
BWAY
|
-6.88 M | $ 24.33 | 5.28 % | $ 99.4 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 23.41 | 0.47 % | $ 252 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 39.7 | 0.92 % | $ 1.1 B | ||
|
Co-Diagnostics
CODX
|
-11.9 M | $ 6.0 | -3.07 % | $ 176 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
-487 M | $ 70.68 | 4.87 % | $ 27.3 B | ||
|
BioNano Genomics
BNGO
|
-2.64 M | $ 1.58 | - | $ 2.01 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Guardant Health
GH
|
646 M | $ 107.76 | -2.19 % | $ 13.2 B | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Illumina
ILMN
|
-494 M | $ 145.25 | 2.96 % | $ 23.1 B | ||
|
IQVIA Holdings
IQV
|
11.2 B | $ 241.11 | -0.55 % | $ 43.7 B | ||
|
CareDx, Inc
CDNA
|
-48 M | $ 20.41 | 19.15 % | $ 1.1 B | ||
|
Danaher Corporation
DHR
|
13.6 B | $ 238.83 | 0.2 % | $ 175 B | ||
|
Celcuity
CELC
|
82.8 M | $ 104.34 | -2.95 % | $ 4.12 B | ||
|
DarioHealth Corp.
DRIO
|
-12.1 M | $ 11.97 | -1.56 % | $ 340 M | ||
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 3.19 | -5.62 % | $ 102 K | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
-346 M | $ 67.28 | -0.41 % | $ 4.66 B | ||
|
Exact Sciences Corporation
EXAS
|
-560 M | $ 102.23 | 0.11 % | $ 18.9 B | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 28.16 | 1.11 % | $ 851 M | ||
|
Medpace Holdings
MEDP
|
-520 M | $ 599.7 | 0.79 % | $ 18.6 B | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Myriad Genetics
MYGN
|
115 M | $ 6.56 | -0.3 % | $ 594 M | ||
|
Charles River Laboratories International
CRL
|
2.1 B | $ 219.73 | -0.62 % | $ 11.3 B | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
National Research Corporation
NRC
|
30.1 M | $ 20.3 | 2.94 % | $ 498 M | ||
|
Mettler-Toledo International
MTD
|
1.8 B | $ 1 486.95 | 0.1 % | $ 31.6 B | ||
|
Natera
NTRA
|
-177 M | $ 233.65 | -0.28 % | $ 23 B | ||
|
ENDRA Life Sciences
NDRA
|
-4.37 M | $ 4.51 | -3.01 % | $ 2.42 M | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
Neogen Corporation
NEOG
|
751 M | $ 9.33 | -3.01 % | $ 2.02 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 175.05 | 0.34 % | $ 19.4 B | ||
|
Biodesix
BDSX
|
14.5 M | $ 8.2 | 50.18 % | $ 1.06 B | ||
|
Laboratory Corporation of America Holdings
LH
|
4 B | $ 249.91 | -0.75 % | $ 21 B | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 180.43 | -0.52 % | $ 14.9 B | ||
|
IDEXX Laboratories
IDXX
|
183 M | $ 722.17 | 1.24 % | $ 59.6 B |